ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 232 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $31,110,164 | -3.8% | 1,954,156 | -1.2% | 0.01% | -22.2% |
| Q3 2022 | $32,346,272 | +37.9% | 1,977,156 | +18.7% | 0.01% | +50.0% |
| Q2 2022 | $23,463,556 | -19.4% | 1,665,263 | +38.5% | 0.01% | 0.0% |
| Q1 2022 | $29,117,260 | +15.7% | 1,202,199 | +11.5% | 0.01% | +20.0% |
| Q4 2021 | $25,165,000 | +14.7% | 1,078,199 | -18.3% | 0.01% | 0.0% |
| Q3 2021 | $21,932,000 | -23.6% | 1,320,399 | +12.1% | 0.01% | -16.7% |
| Q2 2021 | $28,719,000 | +30.5% | 1,177,496 | +38.1% | 0.01% | +20.0% |
| Q1 2021 | $21,999,000 | -62.3% | 852,671 | -22.0% | 0.01% | -64.3% |
| Q4 2020 | $58,407,000 | +4.6% | 1,092,532 | -19.3% | 0.01% | -6.7% |
| Q3 2020 | $55,837,000 | -10.4% | 1,353,618 | +5.2% | 0.02% | -16.7% |
| Q2 2020 | $62,341,000 | +10.0% | 1,286,187 | -4.1% | 0.02% | -10.0% |
| Q1 2020 | $56,679,000 | +4.4% | 1,341,504 | +5.8% | 0.02% | +33.3% |
| Q4 2019 | $54,268,000 | +32.6% | 1,268,528 | +11.6% | 0.02% | +15.4% |
| Q3 2019 | $40,925,000 | +36.1% | 1,137,126 | +1.1% | 0.01% | +44.4% |
| Q2 2019 | $30,077,000 | +7.0% | 1,125,191 | +7.5% | 0.01% | 0.0% |
| Q1 2019 | $28,114,000 | +78.9% | 1,047,051 | +7.7% | 0.01% | +50.0% |
| Q4 2018 | $15,717,000 | +12.7% | 971,976 | +44.6% | 0.01% | +20.0% |
| Q3 2018 | $13,950,000 | +36.0% | 671,976 | 0.0% | 0.01% | +25.0% |
| Q2 2018 | $10,261,000 | -32.7% | 671,976 | -1.0% | 0.00% | -33.3% |
| Q1 2018 | $15,249,000 | -36.7% | 678,676 | -15.2% | 0.01% | -33.3% |
| Q4 2017 | $24,103,000 | -20.1% | 800,491 | 0.0% | 0.01% | -18.2% |
| Q3 2017 | $30,154,000 | +35.1% | 800,491 | 0.0% | 0.01% | +22.2% |
| Q2 2017 | $22,326,000 | -27.3% | 800,491 | -10.3% | 0.01% | -30.8% |
| Q1 2017 | $30,697,000 | +27.6% | 892,884 | +7.1% | 0.01% | +18.2% |
| Q4 2016 | $24,050,000 | -5.1% | 833,906 | 0.0% | 0.01% | -8.3% |
| Q3 2016 | $25,336,000 | +0.9% | 833,906 | +7.8% | 0.01% | 0.0% |
| Q2 2016 | $25,119,000 | +16.1% | 773,840 | 0.0% | 0.01% | +9.1% |
| Q1 2016 | $21,637,000 | -23.1% | 773,840 | -2.0% | 0.01% | -21.4% |
| Q4 2015 | $28,144,000 | +7.8% | 789,447 | 0.0% | 0.01% | 0.0% |
| Q3 2015 | $26,107,000 | -11.4% | 789,447 | +12.2% | 0.01% | -6.7% |
| Q2 2015 | $29,460,000 | +40.8% | 703,443 | +9.5% | 0.02% | +50.0% |
| Q1 2015 | $20,929,000 | -1.5% | 642,203 | -4.1% | 0.01% | -9.1% |
| Q4 2014 | $21,253,000 | +18.6% | 669,391 | -7.5% | 0.01% | +10.0% |
| Q3 2014 | $17,916,000 | -45.2% | 723,595 | -50.0% | 0.01% | +11.1% |
| Q2 2014 | $32,692,000 | – | 1,447,190 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |